Skip to main content
. 2015 Sep 1;3(5):e00178. doi: 10.1002/prp2.178

Figure 7.

Figure 7

Combination activity of Bcl-2 inhibitors with BR in the systemic Granta 519-LMC model. (A) Combination activity of BR (25/10 mg·kg−1, i.v. q.d. × 1) and navitoclax or venetoclax (100 mg·kg−1·day−1, p.o. q.d. × 14). Graphs represent dorsal measurements to capture brain and spinal responses. Green arrow represents BR administration, blue and purple bars represent navitoclax and venetoclax dosing period, respectively. Inset shows %TGD values for each treatment group. (B) Representative images of mice treated with BR and/or navitoclax or venetoclax. Data presented as mean BLI ± SEM. *< 0.05 versus vehicle. †< 0.05 versus BR monotherapy.